GeneralNeutralBlockonomi · 4h ago6/10
📰
Novo Nordisk (NVO) Stock: Can Amycretin Revive the Struggling Weight-Loss Giant?
Novo Nordisk's experimental weight-loss drug Amycretin demonstrated 14.6% weight loss in phase 2 trials, positioning it as a potential competitor in the GLP-1 market dominated by Ozempic and Wegovy. The announcement comes as NVO stock has declined 68%, with upcoming ADA 2026 data on Wegovy expected to provide additional catalyst for the struggling pharmaceutical giant.
$ADA